RetinalGenix Technologies Inc. (RTGN)

3.5000 0.0000 (0.00%) As of 01:47PM EDT. Market open.

RetinalGenix Technologies Inc.

1450 North Mcdowell Boulevard
Suite 150
Petaluma, CA 94954
United States
415 578 9583
https://retinalgenix.com

Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Jerry Katzman	CEO, President & Chairman	N/A	N/A	1953
Mr. Virender K. Ahluwalia	Interim Chief Financial Officer	N/A	N/A	1958

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing solutions to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. Its products include the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Petaluma, California. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.

Corporate Governance

RetinalGenix Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.